Beschreibung:
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>Atherosclerotic non-obstructive coronary artery disease (NObCAD) is frequently observed in patients referred for coronary angiography. No available data exist for the long-term prognosis of NObCAD patients beyond 10 years.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Purpose</jats:title>
<jats:p>We sought to compare the 15- and 20-year survival among patients presenting with chronic stable angina who had smooth coronary vessels, NobCAD, and obstructive (ObCAD), on invasive coronary angiography.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Coronary angiography of 671 consecutive patients presented with suspected CAD were retrospectively evaluated from single center registry between January and December 1998 and linked to administrative databases for outcomes evaluation. No CAD, NobCAD, and ObCAD were defined as 0%, 1% to 49%, and ≥50% luminal narrowing in epicardial coronary artery, respectively. The 15- and the 20-year survival rates were compared by Kaplan-Meier curve and multivariate Cox proportional hazards regression was used to identify significant independent predictors of mortality.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Of 613 individuals (78.7% men with median age of 55.6 (51.0–65.2) years), 74 (12.1%) had normal coronary arteries, 42 (6.9%) had NobCAD, and 497 (81%) had ObCAD. The 15- and the 20-year survival rates were 89%, 66.7%, 62.4% and 79.7%, 54.7%, 42,5% in patients with normal, NobCAD, and ObCAD, respectively, (P=0.050 for no versus NobCAD; P=0.001 for no versus ObCAD at 20-year), These angiographic severity categories showed a strong gradient (P&lt;0.001) (Figure 1). At 15-year follow-up, both ObCAD (adjusted HR=2.42, 95% CI (1.21–4.85), p=0.013) and NobCAD patients (HR=2.65, 95% CI (1.15–6.11), p=0.023) showed higher mortality compared to no CAD group. Independent predictors of mortality were, obstructive CAD (HR=2.34, 95% CI (1.407–3.916), P=0.001 for no versus NobCAD; HR=1.93, 95% CI (1.0–3.72), P=0.050, for no versus obstructive CAD), and age at addmission (HR=1.06, 95% CI (1.04–1.07), P&lt;0.001).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>The result of this analysis highlighted the less benign course of NobCAD that carries a mortality risk similar to patients with ObCAD at 15-and at 20-year follow-up. These findings support the need for aggressive anti-atherosclerotic drug therapy in such individuals and underscore the necessary efforts to improve the risk stratification and management of patients with non-obstructive CAD.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding Acknowledgement</jats:title>
<jats:p>Type of funding source: None</jats:p>
</jats:sec>